What question did this study set out to answer?

To determine response rates, failure-free survival, overall survival, and toxicity of rituximab combined with an intensive alternating chemotherapy regimen in previously untreated aggressive mantle-cell lymphoma.

September 7, 2005Journal of Clinical OncologyOpen Access

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

View Full Paper

Ask AI

Bookmark

Authors

JRJorge RomagueraThe University of Texas MD Anderson Cancer Center LFLuis FayadOntario Institute for Cancer Research MRMaria Alma RodriguezThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Phase II trial demonstrates high response rates with alternating chemoimmunotherapy in mantle-cell lymphoma, indicating durable remissions despite notable toxicity.

Key Points

To determine response rates, failure-free survival, overall survival, and toxicity of rituximab combined with an intensive alternating chemotherapy regimen in previously untreated aggressive mantle-cell lymphoma.
Prospective phase II trial evaluating 97 assessable patients with previously untreated aggressive mantle-cell lymphoma.
Treatment consisted of rituximab plus hyper-CVAD alternating every 21 days with rituximab plus high-dose methotrexate and cytarabine for 6 to 8 cycles.
The overall response rate was 97%, with 87% of patients achieving a complete response or unconfirmed complete response.
At a median follow-up of 40 months, the 3-year failure-free survival rate was 64% (73% in patients aged ≤65 years) and the 3-year overall survival rate was 82%.
Significant hematologic toxicities occurred, leading to 8 treatment-related deaths (8%), including 5 acute toxicity deaths and 4 secondary cases of myelodysplasia or acute myeloid leukemia.

Cite This Study

Romaguera et al. (2005) studied this question.

synapsesocial.com/papers/6a0cabf3c63d985fc0886071 https://doi.org/10.1200/jco.2005.01.1825

View Full Paper

Ask AI

Bookmark

Implication

Phase II trial demonstrates high response rates with alternating chemoimmunotherapy in mantle-cell lymphoma, indicating durable remissions despite notable toxicity.

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

Discussion

Member takes

Implication

Key Points

Cite This Study

High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider